Biocartis Group NV (BCART) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biocartis Group NV (BCART) has a cash flow conversion efficiency ratio of 0.542x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-29.29 Million ≈ $-34.24 Million USD) by net assets (€-53.99 Million ≈ $-63.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biocartis Group NV (BCART) liquidity interval to measure how many days the company can operate on defensive assets alone.
Biocartis Group NV - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Biocartis Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biocartis Group NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocartis Group NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bio Planet SA
WAR:BIP
|
-0.010x |
|
NEXTCHIP Co. Ltd
KQ:092600
|
-0.132x |
|
Pureprofile Ltd
AU:PPL
|
0.202x |
|
Galaxia SM Inc
KO:011420
|
0.082x |
|
FASOO.COM Co Ltd
KQ:150900
|
0.045x |
|
Radiant Globaltech Bhd
KLSE:0202
|
0.005x |
|
Chinese People Holdings Company Limited
F:KEH
|
0.006x |
|
Pegasus Heights Bhd
KLSE:4464
|
0.018x |
Annual Cash Flow Conversion Efficiency for Biocartis Group NV (2012–2022)
The table below shows the annual cash flow conversion efficiency of Biocartis Group NV from 2012 to 2022. For the full company profile with market capitalisation and key ratios, see Biocartis Group NV stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €-30.28 Million ≈ $-35.41 Million |
€-44.85 Million ≈ $-52.44 Million |
1.481x | -23.60% |
| 2021-12-31 | €-33.90 Million ≈ $-39.63 Million |
€-65.72 Million ≈ $-76.83 Million |
1.939x | +281.81% |
| 2020-12-31 | €36.82 Million ≈ $43.05 Million |
€-39.27 Million ≈ $-45.91 Million |
-1.066x | -66.04% |
| 2019-12-31 | €84.48 Million ≈ $98.76 Million |
€-54.25 Million ≈ $-63.43 Million |
-0.642x | -33.59% |
| 2018-12-31 | €87.35 Million ≈ $102.12 Million |
€-41.99 Million ≈ $-49.09 Million |
-0.481x | -53.54% |
| 2017-12-31 | €132.24 Million ≈ $154.60 Million |
€-41.41 Million ≈ $-48.41 Million |
-0.313x | +43.10% |
| 2016-12-31 | €96.89 Million ≈ $113.27 Million |
€-53.31 Million ≈ $-62.33 Million |
-0.550x | -170.72% |
| 2015-12-31 | €114.92 Million ≈ $134.35 Million |
€-23.36 Million ≈ $-27.31 Million |
-0.203x | +88.51% |
| 2014-12-31 | €20.28 Million ≈ $23.71 Million |
€-35.88 Million ≈ $-41.95 Million |
-1.769x | -37.31% |
| 2013-12-31 | €31.95 Million ≈ $37.36 Million |
€-41.18 Million ≈ $-48.14 Million |
-1.289x | -14.93% |
| 2012-12-31 | €36.80 Million ≈ $43.02 Million |
€-41.26 Million ≈ $-48.24 Million |
-1.121x | -- |
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more